189 related articles for article (PubMed ID: 22749842)
1. Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice.
Lipina TV; Palomo V; Gil C; Martinez A; Roder JC
Neuropharmacology; 2013 Jan; 64():205-14. PubMed ID: 22749842
[TBL] [Abstract][Full Text] [Related]
2. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
[TBL] [Abstract][Full Text] [Related]
3. Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents.
Gacsályi I; Nagy K; Pallagi K; Lévay G; Hársing LG; Móricz K; Kertész S; Varga P; Haller J; Gigler G; Szénási G; Barkóczy J; Bíró J; Spedding M; Antoni FA
Neuropharmacology; 2013 Jan; 64():254-63. PubMed ID: 22824189
[TBL] [Abstract][Full Text] [Related]
4. Synergistic interactions between PDE4B and GSK-3: DISC1 mutant mice.
Lipina TV; Wang M; Liu F; Roder JC
Neuropharmacology; 2012 Mar; 62(3):1252-62. PubMed ID: 21376063
[TBL] [Abstract][Full Text] [Related]
5. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
Sierksma AS; Rutten K; Sydlik S; Rostamian S; Steinbusch HW; van den Hove DL; Prickaerts J
Neuropharmacology; 2013 Jan; 64():124-36. PubMed ID: 22771768
[TBL] [Abstract][Full Text] [Related]
6. Co-learning facilitates memory in mice: a new avenue in social neuroscience.
Lipina TV; Roder JC
Neuropharmacology; 2013 Jan; 64():283-93. PubMed ID: 22776545
[TBL] [Abstract][Full Text] [Related]
7. Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study.
Winterer G; Gallinat J; Brinkmeyer J; Musso F; Kornhuber J; Thuerauf N; Rujescu D; Favis R; Sun Y; Franc MA; Ouwerkerk-Mahadevan S; Janssens L; Timmers M; Streffer JR
Neuropharmacology; 2013 Jan; 64():197-204. PubMed ID: 22766391
[TBL] [Abstract][Full Text] [Related]
8. Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia--a path model investigation.
Stenberg JH; Terevnikov V; Joffe M; Tiihonen J; Chukhin E; Burkin M; Joffe G
Neuropharmacology; 2013 Jan; 64():248-53. PubMed ID: 22750079
[TBL] [Abstract][Full Text] [Related]
9. Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target.
Barak S; Weiner I
Pharmacol Biochem Behav; 2011 Aug; 99(2):164-89. PubMed ID: 21420999
[TBL] [Abstract][Full Text] [Related]
10. The nicotinic α7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys.
Cannon CE; Puri V; Vivian JA; Egbertson MS; Eddins D; Uslaner JM
Neuropharmacology; 2013 Jan; 64():191-6. PubMed ID: 22659472
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease.
Perez-Gonzalez R; Pascual C; Antequera D; Bolos M; Redondo M; Perez DI; Pérez-Grijalba V; Krzyzanowska A; Sarasa M; Gil C; Ferrer I; Martinez A; Carro E
Neurobiol Aging; 2013 Sep; 34(9):2133-45. PubMed ID: 23582662
[TBL] [Abstract][Full Text] [Related]
12. GluN2C/GluN2D subunit-selective NMDA receptor potentiator CIQ reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice.
Suryavanshi PS; Ugale RR; Yilmazer-Hanke D; Stairs DJ; Dravid SM
Br J Pharmacol; 2014 Feb; 171(3):799-809. PubMed ID: 24236947
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: Role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission.
Wang D; Noda Y; Zhou Y; Nitta A; Furukawa H; Nabeshima T
Neuropharmacology; 2007 Sep; 53(3):379-89. PubMed ID: 17632185
[TBL] [Abstract][Full Text] [Related]
14. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
Barak S; Weiner I
Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109
[TBL] [Abstract][Full Text] [Related]
15. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.
Kanes SJ; Tokarczyk J; Siegel SJ; Bilker W; Abel T; Kelly MP
Neuroscience; 2007 Jan; 144(1):239-46. PubMed ID: 17081698
[TBL] [Abstract][Full Text] [Related]
16. Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol.
Gaisler-Salomon I; Weiner I
Psychopharmacology (Berl); 2003 Apr; 166(4):333-42. PubMed ID: 12599023
[TBL] [Abstract][Full Text] [Related]
17. AMPAKINE enhancement of social interaction in the BTBR mouse model of autism.
Silverman JL; Oliver CF; Karras MN; Gastrell PT; Crawley JN
Neuropharmacology; 2013 Jan; 64(1):268-82. PubMed ID: 22801296
[TBL] [Abstract][Full Text] [Related]
18. Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs.
Barak S; Weiner I
Int J Neuropsychopharmacol; 2009 Mar; 12(2):227-41. PubMed ID: 18687163
[TBL] [Abstract][Full Text] [Related]
19. Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia.
Barak S; Arad M; De Levie A; Black MD; Griebel G; Weiner I
Neuropsychopharmacology; 2009 Jun; 34(7):1753-63. PubMed ID: 19158670
[TBL] [Abstract][Full Text] [Related]
20. Repeated low dose of phencyclidine administration impairs spatial learning in mice: blockade by clozapine but not by haloperidol.
Beraki S; Kuzmin A; Tai F; Ogren SO
Eur Neuropsychopharmacol; 2008 Jul; 18(7):486-97. PubMed ID: 18242064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
